The USA-based company's lead product, obexelimab (ZB012), is a Phase III, novel bifunctional antibody with first-in-class potential that inhibits B-cell lineages that express CD19. Zenas acquired exclusive worldwide rights to obexelimab from Xencor.

In November 2022, the company announced proceeds of $118 million in connection with the issuance of Series B preferred shares.